EGFR and head and neck squamous cell carcinoma: The study used RM-1929, combining an IR700 dye with Erbitux® (cetuximab), an FDA-approved antibody that targets EGFR, highly expressed in squamous cell carcinomas of the head and neck (HNSCC).